Page 13 of the presentation:
"Monepantel displays a superior safety, tolerability and preliminary efficacy profile to the leading FDA
approved drug Relyvrio®"
This is probably as good as it gets at phase 1. Better then I thought especially with the life expectancy.
Key takeaway being 13.5-56.5 months additional life expectancy compared to Relyvrio 8-9 months?
Seminar about to start.
Ann: Presentation - Phase 1 Top-Line Results, page-7
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.005(2.38%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $325.8K | 1.512M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 236217 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 78289 | 2 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.005 ( 2.23 %) |
||||
| Open | High | Low | Volume | ||
| 21.5¢ | 22.5¢ | 21.0¢ | 629786 | ||
| Last updated 15.58pm 03/06/2024 ? | |||||
| PAA (ASX) Chart |